Peptide-based anticancer vaccines: Recent advances and future perspectives

Current Medicinal Chemistry

Volumn 16, Issue 36, 2009, Pages 4779-4796

  Mocellin, S ^a   Pilati, P ^a   Nitti, D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100(209-2M); GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; IPILIMUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONTANIDE ISA 51; PEPTIDE VACCINE; SYNTHETIC PEPTIDE; TICILIMUMAB; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; WART VIRUS VACCINE;

ACTINIC KERATOSIS; ADVANCED CANCER; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG DESIGN; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RELEASE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLAMMATION; LUNG CANCER; MELANOMA; MELANOMA B16; NONHUMAN; PAGET SKIN DISEASE; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VERRUCA VULGARIS;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; EPITOPES; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; NEOPLASMS; PEPTIDES;

EID: 71949118684     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789909648     Document Type: Review

References (258)

1. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol., 2004, 22, 329-360.
2. Mocellin, S.; Mandruzzato, S.; Bronte, V.; Lise, M.; Nitti, D. Part I: Vaccines for solid tumours. Lancet Oncol., 2004, 5, 681-689.
3. Choudhury, A.; Mosolits, S.; Kokhaei, P.; Hansson, L.; Palma, M.; Mellstedt, H. Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv. Cancer Res., 2006, 95, 147-202. (Pubitemid 44066526)
4. Rosenberg, S.A. Progress in human tumour immunology and immunotherapy. Nature, 2001, 411, 380-384.
5. Kwak, L.W.; Campbell, M.J.; Czerwinski, D.K.; Hart, S.; Miller, R.A.; Levy, R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med., 1992, 327, 1209-1215.
6. Bendandi, M.; Gocke, C.D.; Kobrin, C.B.; Benko, F.A.; Sternas, L.A.; Pennington, R.; Watson, T.M.; Reynolds, C.W.; Gause, B.L.; Duffey, P.L.; Jaffe, E.S.; Creekmore, S.P.; Longo, D.L.; Kwak, L.W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med., 1999, 5, 1171-1177.
7. Inoges, S.; Rodriguez-Calvillo, M.; Zabalegui, N.; Lopez-Diaz de Cerio, A.; Villanueva, H.; Soria, E.; Suarez, L.; Rodriguez-Caballero, A.; Pastor, F.; Garcia-Munoz, R.; Panizo, C.; Perez-Calvo, J.; Melero, I.; Rocha, E.; Orfao, A.; Bendandi, M. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl. Cancer Inst., 2006, 98, 1292-1301. (Pubitemid 44530725)
8. Houot, R.; Levy, R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev., 2009, 23, 137-142.
9. Cormier, J.N.; Abati, A.; Fetsch, P.; Hijazi, Y.M.; Rosenberg, S.A.; Marincola, F.M.; Topalian, S.L. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J. Immunother., 1998, 21, 27-31.
10. Marincola, F.M.; Jaffee, E.M.; Hicklin, D.J.; Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 2000, 74, 181-273.
11. Hodge, J.W.; Greiner, J.W.; Tsang, K.Y.; Sabzevari, H.; Kudo-Saito, C.; Grosenbach, D.W.; Gulley, J.L.; Arlen, P.M.; Marshall, J.L.; Panicali, D.; Schlom, J. Costimulatory molecules as adjuvants for immunotherapy. Front. Biosci., 2006, 11, 788-803.
12. Zang, X.; Allison, J.P. The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res., 2007, 13, 5271-5279. (Pubitemid 47510350)
13. Restifo, N.P.; Marincola, F.M.; Kawakami, Y.; Taubenberger, J.; Yannelli, J.R.; Rosenberg, S.A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst., 1996, 88, 100-108. (Pubitemid 2619238)
14. Seliger, B.; Ritz, U.; Abele, R.; Bock, M.; Tampe, R.; Sutter, G.; Drexler, I.; Huber, C.; Ferrone, S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res., 2001, 61, 8647-8650. (Pubitemid 34013870)
15. Rabinovich, G.A.; Gabrilovich, D.; Sotomayor, E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol., 2007, 25, 267-296
16. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol., 2006, 6, 715-727. (Pubitemid 44453458)
17. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer, 2005, 5, 263-274. (Pubitemid 40488632)
18. Mocellin, S.; Rossi, C.R.; Nitti, D.; Lise, M.; Marincola, F.M. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochim. Biophys. Acta, 2003, 1653, 61-71.
19. Purcell, A.W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov., 2007, 6, 404-414. (Pubitemid 46696551)
20. Fujimura, T.; Ohta, T.; Oyama, K.; Miyashita, T.; Miwa, K. Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J. Gastrointest. Cancer, 2007, 38, 78-82.
21. Bijker, M.S.; Melief, C.J.; Offringa, R.; van der Burg, S.H. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev. Vaccines, 2007, 6, 591-603. (Pubitemid 47281301)
22. Townsend, A.R.; Rothbard, J.; Gotch, F.M.; Bahadur, G.; Wraith, D.; McMichael, A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell, 1986, 44, 959-968.
23. van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991, 254, 1643-1647. (Pubitemid 21917508)
24. Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pel, A.; De Plaen, E.; Amar-Costesec, A.; Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 1992, 176, 1453-1457.
25. Aichele, P.; Hengartner, H.; Zinkernagel, R.M.; Schulz, M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med., 1990, 171, 1815-1820. (Pubitemid 20167572)
26. Velders, M.P.; Nieland, J.D.; Rudolf, M.P.; Loviscek, K.; Weijzen, S.; de Visser, K.E.; Macedo, M.F.; Carbone, M.; Kast, W.M. Identification of peptides for immunotherapy of cancer. It is worth the effort. Crit. Rev. Immunol., 1998, 18, 7-27. (Pubitemid 128670053)
27. Van Der Bruggen, P.; Zhang, Y.; Chaux, P.; Stroobant, V.; Panichelli, C.; Schultz, E.S.; Chapiro, J.; Van Den Eynde, B.J.; Brasseur, F.; Boon, T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev., 2002, 188, 51-64. (Pubitemid 35398865)
28. Andersen, M.H.; Svane, I.M.; Becker, J.C.; Straten, P.T. The universal character of the tumor-associated antigen survivin. Clin. Cancer Res., 2007, 13, 5991-5994.
29. Morris, L.F.; Ribas, A. Therapeutic cancer vaccines. Surg. Oncol. Clin. N. Am., 2007, 16, 819-831, ix.
30. Kanodia, S.; Kast, W.M. Peptide-based vaccines for cancer: realizing their potential. Expert Rev. Vaccines, 2008, 7, 1533-1545.
31. Dao, T.; Scheinberg, D.A. Peptide vaccines for myeloid leukaemias. Best Pract. Res. Clin. Haematol., 2008, 21, 391-404.
32. Provenzano, M.; Panelli, M.C.; Mocellin, S.; Bracci, L.; Sais, G.; Stroncek, D.F.; Spagnoli, G.C.; Marincola, F.M. MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts. Trends Mol. Med., 2006, 12, 465-472.
33. Rotzschke, O.; Falk, K.; Deres, K.; Schild, H.; Norda, M.; Metzger, J.; Jung, G.; Rammensee, H.G. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature, 1990, 348, 252-254. (Pubitemid 20383092)
34. Hunt, D.F.; Henderson, R.A.; Shabanowitz, J.; Sakaguchi, K.; Michel, H.; Sevilir, N.; Cox, A.L.; Appella, E.; Engelhard, V.H. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science, 1992, 255, 1261-1263.
35. Liu, R.; Enstrom, A.M.; Lam, K.S. Combinatorial peptide library methods for immunobiology research. Exp. Hematol., 2003, 31, 11-30.
36. Tsurui, H.; Takahashi, T. Prediction of T-cell epitope. J. Pharmacol. Sci., 2007, 105, 299-316.
37. Houghton, C.S.; Engelhorn, M.E.; Liu, C.; Song, D.; Gregor, P.; Livingston, P.O.; Orlandi, F.; Wolchok, J.D.; McCracken, J.; Houghton, A.N.; Guevara-Patino, J.A. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine, 2007, 25, 5330-5342.
38. Cornett, W.R.; McCall, L.M.; Petersen, R.P.; Ross, M.I.; Briele, H.A.; Noyes, R.D.; Sussman, J.J.; Kraybill, W.G.; Kane, J.M., 3rd; Alexander, H.R.; Lee, J.E.; Mansfield, P.F.; Pingpank, J.F.; Winchester, D.J.; White, R.L., Jr.; Chadaram, V.; Herndon, J.E., 2nd; Fraker, D.L.; Tyler, D.S. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J. Clin. Oncol., 2006, 24, 4196-4201.
39. Salter, R.D.; Cresswell, P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J., 1986, 5, 943-949.
40. Schumacher, T.N.; De Bruijn, M.L.; Vernie, L.N.; Kast, W.M.; Melief, C.J.; Neefjes, J.J.; Ploegh, H.L. Peptide selection by MHC class I molecules. Nature, 1991, 350, 703-706. (Pubitemid 21912301)
41. Schumacher, T.N.; Heemels, M.T.; Neefjes, J.J.; Kast, W.M.; Melief, C.J.; Ploegh, H.L. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell, 1990, 62, 563-567. (Pubitemid 20263225)
42. Lyerly, H.K. Quantitating cellular immune responses to cancer vaccines. Semin. Oncol., 2003, 30, 9-16. (Pubitemid 36897514)
43. Malyguine, A.; Strobl, S.; Zaritskaya, L.; Baseler, M.; Shafer-Weaver, K. New approaches for monitoring CTL activity in clinical trials. Adv. Exp. Med. Biol., 2007, 601, 273-284.
44. Keilholz, U.; Martus, P.; Scheibenbogen, C. Immune monitoring of T-cell responses in cancer vaccine development. Clin. Cancer Res., 2006, 12, 2346s-2352s.
45. Hickman, H.D.; Luis, A.D.; Buchli, R.; Few, S.R.; Sathiamurthy, M.; VanGundy, R.S.; Giberson, C.F.; Hildebrand, W.H. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J. Immunol., 2004, 172, 2944-2952.
46. Speir, J.A.; Abdel-Motal, U.M.; Jondal, M.; Wilson, I.A. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity, 1999, 10, 51-61.
47. Backlund, J.; Carlsen, S.; Hoger, T.; Holm, B.; Fugger, L.; Kihlberg, J.; Burkhardt, H.; Holmdahl, R. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA, 2002, 99, 9960-9965. (Pubitemid 34831155)
48. van Stipdonk, M.J.; Willems, A.A.; Amor, S.; Persoon-Deen, C.; Travers, P.J.; Boog, C.J.; van Noort, J.M. T cells discriminate between differentially phosphorylated forms of alphaB-crystallin, a major central nervous system myelin antigen. Int. Immunol., 1998, 10, 943-950.
49. McAdam, S.N.; Fleckenstein, B.; Rasmussen, I.B.; Schmid, D.G.; Sandlie, I.; Bogen, B.; Viner, N.J.; Sollid, L.M. T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation. J. Exp. Med., 2001, 193, 1239-1246.
50. Anderson, R.P.; Degano, P.; Godkin, A.J.; Jewell, D.P.; Hill, A.V. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat. Med., 2000, 6, 337-342.
51. Chen, W.; Ede, N.J.; Jackson, D.C.; McCluskey, J.; Purcell, A.W. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J. Immunol., 1996, 157, 1000-1005. (Pubitemid 126449612)
52. Ireland, J.; Herzog, J.; Unanue, E.R. Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization. J. Immunol., 2006, 177, 1421-1425.
53. Engelhard, V.H.; Altrich-Vanlith, M.; Ostankovitch, M.; Zarling, A.L. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol., 2006, 18, 92-97.
54. Hanisch, F.G.; Ninkovic, T. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr. Protein Pept. Sci., 2006, 7, 307-315. (Pubitemid 44237140)
55. Kuckelkorn, U.; Ruppert, T.; Strehl, B.; Jungblut, P.R.; Zimny-Arndt, U.; Lamer, S.; Prinz, I.; Drung, I.; Kloetzel, P.M.; Kaufmann, S.H.; Steinhoff, U. Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J. Exp. Med., 2002, 195, 983-990. (Pubitemid 34412000)
56. Liu, J.Q.; Bai, X.F. Overcoming immune evasion in T cell therapy of cancer: lessons from animal models. Curr. Mol. Med., 2008, 8, 68-75.
57. Smahel, M.; Tejklova, P.; Smahelova, J.; Polakova, I.; Mackova, J. Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape. Cancer Immunol. Immunother., 2008, 57, 823-831. (Pubitemid 351660126)
58. Singh, R.; Paterson, Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res., 2007, 67, 1887-1892. (Pubitemid 46424202)
59. Fikes, J.D.; Sette, A. Design of multi-epitope, analogue-based cancer vaccines. Expert Opin. Biol. Ther., 2003, 3, 985-993. (Pubitemid 37093153)
60. Chianese-Bullock, K.A.; Lewis, S.T.; Sherman, N.E.; Shannon, J.D.; Slingluff, C.L., Jr. Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine, 2009, 27, 1764-1770.
61. Sette, A.; Vitiello, A.; Reherman, B.; Fowler, P.; Nayersina, R.; Kast, W.M.; Melief, C.J.; Oseroff, C.; Yuan, L.; Ruppert, J.; Sidney, J.; del Guercio, M.F.; Southwood, S.; Kubo, R.T.; Chesnut, R.W.; Grey, H.M.; Chisari, F.V. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol., 1994, 153, 5586-5592.
62. Borbulevych, O.Y.; Baxter, T.K.; Yu, Z.; Restifo, N.P.; Baker, B.M. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J. Immunol., 2005, 174, 4812-4820. (Pubitemid 40504564)
63. Irvine, K.R.; Parkhurst, M.R.; Shulman, E.P.; Tupesis, J.P.; Custer, M.; Touloukian, C.E.; Robbins, P.F.; Yafal, A.G.; Greenhalgh, P.; Sutmuller, R.P.; Offringa, R.; Rosenberg, S.A.; Restifo, N.P. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res., 1999, 59, 2536-2540.
64. Chen, J.L.; Stewart-Jones, G.; Bossi, G.; Lissin, N.M.; Wooldridge, L.; Choi, E.M.; Held, G.; Dunbar, P.R.; Esnouf, R.M.; Sami, M.; Boulter, J.M.; Rizkallah, P.; Renner, C.; Sewell, A.; van der Merwe, P.A.; Jakobsen, B.K.; Griffiths, G.; Jones, E.Y.; Cerundolo, V. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med., 2005, 201, 1243-1255.
65. Denkberg, G.; Klechevsky, E.; Reiter, Y. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. J. Immunol., 2002, 169, 4399-4407. (Pubitemid 35178214)
66. Yang, S.; Linette, G.P.; Longerich, S.; Haluska, F.G. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J. Immunol., 2002, 169, 531-539.
67. Meijer, S.L.; Dols, A.; Jensen, S.M.; Hu, H.M.; Miller, W.; Walker, E.; Romero, P.; Fox, B.A.; Urba, W.J. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J. Immunother., 2007, 30, 533-543.
68. Clay, T.M.; Custer, M.C.; McKee, M.D.; Parkhurst, M.; Robbins, P.F.; Kerstann, K.; Wunderlich, J.; Rosenberg, S.A.; Nishimura, M.I. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol., 1999, 162, 1749-1755.
69. Rosenberg, S.A.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.; Marincola, F.M.; Topalian, S.L.; Restifo, N.P.; Dudley, M.E.; Schwarz, S.L.; Spiess, P.J.; Wunderlich, J.R.; Parkhurst, M.R.; Kawakami, Y.; Seipp, C.A.; Einhorn, J.H.; White, D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 1998, 4, 321-327.
70. Sosman, J.A.; Carrillo, C.; Urba, W.J.; Flaherty, L.; Atkins, M.B.; Clark, J.I.; Dutcher, J.; Margolin, K.A.; Mier, J.; Gollob, J.; Kirkwood, J.M.; Panka, D.J.; Crosby, N.A.; O'Boyle, K.; LaFleur, B.; Ernstoff, M.S. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J. Clin. Oncol., 2008, 26, 2292-2298.
71. NCT00019682. Adesleukin with or without vaccine therapy in treating patients with locally advanced or metastatic melanoma. http://clinicaltrialsgov/ show/NCT00019682, (ongoing study).
72. Di Pucchio, T.; Pilla, L.; Capone, I.; Ferrantini, M.; Montefiore, E.; Urbani, F.; Patuzzo, R.; Pennacchioli, E.; Santinami, M.; Cova, A.; Sovena, G.; Arienti, F.; Lombardo, C.; Lombardi, A.; Caporaso, P.; D'Atri, S.; Marchetti, P.; Bonmassar, E.; Parmiani, G.; Belardelli, F.; Rivoltini, L. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res., 2006, 66, 4943-4951.
73. Pinilla-Ibarz, J.; May, R.J.; Korontsvit, T.; Gomez, M.; Kappel, B.; Zakhaleva, V.; Zhang, R.H.; Scheinberg, D.A. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia, 2006, 20, 2025-2033.
74. Zirlik, K.M.; Zahrieh, D.; Neuberg, D.; Gribben, J.G. Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood, 2006, 108, 3865-3870.
75. Tangri, S.; Ishioka, G.Y.; Huang, X.; Sidney, J.; Southwood, S.; Fikes, J.; Sette, A. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med., 2001, 194, 833-846. (Pubitemid 32983018)
76. Butler, N.S.; Theodossis, A.; Webb, A.I.; Nastovska, R.; Ramarathinam, S.H.; Dunstone, M.A.; Rossjohn, J.; Purcell, A.W.; Perlman, S. Prevention of cytotoxic T cell escape using a heteroclitic subdominant viral T cell determinant. PLoS Pathog., 2008, 4, e1000186.
77. Dyall, R.; Bowne, W.B.; Weber, L.W.; LeMaoult, J.; Szabo, P.; Moroi, Y.; Piskun, G.; Lewis, J.J.; Houghton, A.N.; Nikolic-Zugic, J. Heteroclitic immunization induces tumor immunity. J. Exp. Med., 1998, 188, 1553-1561. (Pubitemid 28516100)
78. Slansky, J.E.; Rattis, F.M.; Boyd, L.F.; Fahmy, T.; Jaffee, E.M.; Schneck, J.P.; Margulies, D.H.; Pardoll, D.M. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity, 2000, 13, 529-538.
79. Sette, A.; Newman, M.; Livingston, B.; McKinney, D.; Sidney, J.; Ishioka, G.; Tangri, S.; Alexander, J.; Fikes, J.; Chesnut, R. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens, 2002, 59, 443-451.
80. Scardino, A.; Alimandi, M.; Correale, P.; Smith, S.G.; Bei, R.; Firat, H.; Cusi, M.G.; Faure, O.; Graf-Dubois, S.; Cencioni, G.; Marrocco, J.; Chouaib, S.; Lemonnier, F.A.; Jackson, A.M.; Kosmatopoulos, K. A polyepitope DNA vaccine targeted to Her- 2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res., 2007, 67, 7028-7036.
81. Chiong, B.; Wong, R.; Lee, P.; Delto, J.; Scotland, R.; Lau, R.; Weber, J. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine. J. Immunother., 2004, 27, 368-379. (Pubitemid 39121925)
82. Hou, Y.; Kavanagh, B.; Fong, L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J. Immunol., 2008, 180, 1526-1534.
83. Frank, C.; Hundemer, M.; Ho, A.D.; Goldschmidt, H.; Witzens-Harig, M. Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk. Lymphoma, 2008, 49, 779-785.
84. Brown, M.E.; Miao, H.; McKee, M.D. Recognition of carcinoembryonic antigen peptide and heteroclitic peptide by peripheral blood T lymphocytes. J. Immunother., 2007, 30, 350-358.
85. Speiser, D.E.; Baumgaertner, P.; Voelter, V.; Devevre, E.; Barbey, C.; Rufer, N.; Romero, P. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA, 2008, 105, 3849-3854. (Pubitemid 351723488)
86. Stuge, T.B.; Holmes, S.P.; Saharan, S.; Tuettenberg, A.; Roederer, M.; Weber, J.S.; Lee, P.P. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med., 2004, 1, e28.
87. Blake, J.; Johnston, J.V.; Hellstrom, K.E.; Marquardt, H.; Chen, L. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. J. Exp. Med., 1996, 184, 121-130. (Pubitemid 26247221)
88. Sharav, T.; Wiesmuller, K.H.; Walden, P. Mimotope vaccines for cancer immunotherapy. Vaccine, 2007, 25, 3032-3037.
89. Wang, Y.; Rubtsov, A.; Heiser, R.; White, J.; Crawford, F.; Marrack, P.; Kappler, J.W. Using a baculovirus display library to identify MHC class I mimotopes. Proc. Natl. Acad. Sci. USA, 2005, 102, 2476-2481.
90. Zhao, L.; Liu, Z.; Fan, D. Overview of mimotopes and related strategies in tumor vaccine development. Expert Rev. Vaccines, 2008, 7, 1547-1555.
91. Wierzbicki, A.; Gil, M.; Ciesielski, M.; Fenstermaker, R.A.; Kaneko, Y.; Rokita, H.; Lau, J.T.; Kozbor, D. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells. J. Immunol., 2008, 181, 6644-6653.
92. Kowalczyk, A.; Wierzbicki, A.; Gil, M.; Bambach, B.; Kaneko, Y.; Rokita, H.; Repasky, E.; Fenstermaker, R.; Brecher, M.; Ciesielski, M.; Kozbor, D. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol. Immunother., 2007, 56, 1443-1458. (Pubitemid 47024709)
93. Luo, W.; Ko, E.; Hsu, J.C.; Wang, X.; Ferrone, S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J. Immunol., 2006, 176, 6046-6054.
94. Bolesta, E.; Kowalczyk, A.; Wierzbicki, A.; Rotkiewicz, P.; Bambach, B.; Tsao, C.Y.; Horwacik, I.; Kolinski, A.; Rokita, H.; Brecher, M.; Wang, X.; Ferrone, S.; Kozbor, D. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res., 2005, 65, 3410-3418. (Pubitemid 40524627)
95. Tumenjargal, S.; Gellrich, S.; Linnemann, T.; Muche, J.M.; Lukowsky, A.; Audring, H.; Wiesmuller, K.H.; Sterry, W.; Walden, P. Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope. Eur. J. Immunol., 2003, 33, 3175-3185. (Pubitemid 37428350)
96. Sette, A.; Fikes, J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol., 2003, 15, 461-470. (Pubitemid 36934509)
97. Guichard, G.; Zerbib, A.; Le Gal, F.A.; Hoebeke, J.; Connan, F.; Choppin, J.; Briand, J.P.; Guillet, J.G. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumorinfiltrating lymphocytes. J. Med. Chem., 2000, 43, 3803-3808.
98. Webb, A.I.; Dunstone, M.A.; Williamson, N.A.; Price, J.D.; de Kauwe, A.; Chen, W.; Oakley, A.; Perlmutter, P.; McCluskey, J.; Aguilar, M.I.; Rossjohn, J.; Purcell, A.W. T cell determinants incorporating beta-amino acid residues are protease resistant and remain immunogenic in vivo. J. Immunol., 2005, 175, 3810-3818.
99. Steer, D.L.; Lew, R.A.; Perlmutter, P.; Smith, A.I.; Aguilar, M.I. Beta-amino acids: versatile peptidomimetics. Curr. Med. Chem., 2002, 9, 811-822.
100. Marschutz, M.K.; Zauner, W.; Mattner, F.; Otava, A.; Buschle, M.; Bernkop-Schnurch, A. Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration. Peptides, 2002, 23, 1727-1733. (Pubitemid 35279830)
101. McGregor, D.P. Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol., 2008, 8, 616-619.
102. Kast, W.M.; Brandt, R.M.; Melief, C.J. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur. J. Immunol., 1993, 23, 1189-1192.
103. Melief, C.J.; van der Burg, S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer, 2008, 8, 351-360.
104. Zwaveling, S.; Ferreira Mota, S.C.; Nouta, J.; Johnson, M.; Lipford, G.B.; Offringa, R.; van der Burg, S.H.; Melief, C.J. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol., 2002, 169, 350-358.
105. Bijker, M.S.; van den Eeden, S.J.; Franken, K.L.; Melief, C.J.; van der Burg, S.H.; Offringa, R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol., 2008, 38, 1033-1042.
106. Kenter, G.G.; Welters, M.J.; Valentijn, A.R.; Lowik, M.J.; Berends-van der Meer, D.M.; Vloon, A.P.; Drijfhout, J.W.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; Offringa, R.; van der Burg, S.H.; Melief, C.J. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res., 2008, 14, 169-177.
107. Sais, G.; Wyler, S.; Hermanns, T.; Spagnoli, G.; Sulser, T.; Provenzano, M. Impaired immune proinflammatory cytokine profiling in prastate cancer patients upon induction using peptides within polyomavirus BK-P53 binding regions. J. Urol., 2009, 181, 187.
108. Welters, M.J.; Kenter, G.G.; Piersma, S.J.; Vloon, A.P.; Lowik, M.J.; Berends-van der Meer, D.M.; Drijfhout, J.W.; Valentijn, A.R.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; Offringa, R.; Melief, C.J.; van der Burg, S.H. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res., 2008, 14, 178-187.
109. Tindle, R.W.; Fernando, G.J.; Sterling, J.C.; Frazer, I.H. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. USA, 1991, 88, 5887-5891.
110. Dell, K.; Koesters, R.; Gissmann, L. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int. J. Cancer, 2006, 118, 364-372. (Pubitemid 41779076)
111. Karanikas, V.; Hwang, L.A.; Pearson, J.; Ong, C.S.; Apostolopoulos, V.; Vaughan, H.; Xing, P.X.; Jamieson, G.; Pietersz, G.; Tait, B.; Broadbent, R.; Thynne, G.; McKenzie, I.F. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest., 1997, 100, 2783-2792.
112. Karanikas, V.; Colau, D.; Baurain, J.F.; Chiari, R.; Thonnard, J.; Gutierrez-Roelens, I.; Goffinet, C.; Van Schaftingen, E.V.; Weynants, P.; Boon, T.; Coulie, P.G. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res., 2001, 61, 3718-3724.
113. White, K.; Kearns, P.; Toth, I.; Hook, S. Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid-corepeptides. Immunol. Cell Biol., 2004, 82, 517-522. (Pubitemid 39421061)
114. Brandt, E.R.; Sriprakash, K.S.; Hobb, R.I.; Hayman, W.A.; Zeng, W.; Batzloff, M.R.; Jackson, D.C.; Good, M.F. New multideterminant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat. Med., 2000, 6, 455-459.
115. Sadler, K.; Zeng, W.; Jackson, D.C. Synthetic peptide epitope-based polymers: controlling size and determining the efficiency of epitope incorporation. J. Pept. Res., 2002, 60, 150-158.
116. Fitzmaurice, C.J.; Brown, L.E.; McInerney, T.L.; Jackson, D.C. The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants. Vaccine, 1996, 14, 553-560.
117. Katsara, M.; Tselios, T.; Deraos, S.; Deraos, G.; Matsoukas, M.T.; Lazoura, E.; Matsoukas, J.; Apostolopoulos, V. Round and round we go: cyclic peptides in disease. Curr. Med. Chem., 2006, 13, 2221-2232.
118. Blank, V.C.; Pena, C.; Roquin, L.P. A cyclic chimeric interferon-alpha2b peptide induces apoptosis in tumor cells. Cancer Biol. Ther., 2007, 6, 1787-1793. (Pubitemid 351590314)
119. Otvos, L.; Jr. Peptide-based drug design: here and now. Methods Mol. Biol., 2008, 494, 1-8.
120. Torres, C.; Antileo, E.; Epunan, M.J.; Pino, A.M.; Valladares, L.E.; Sierralta, W.D. A cyclic peptide derived from alpha-fetoprotein inhibits the proliferative effects of the epidermal growth factor and estradiol in MCF7 cells. Oncol. Rep., 2008, 19, 1597-1603.
121. Toes, R.E.; Offringa, R.; Blom, R.J.; Melief, C.J.; Kast, W.M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA, 1996, 93, 7855-7860.
122. Toes, R.E.; Blom, R.J.; Offringa, R.; Kast, W.M.; Melief, C.J. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol., 1996, 156, 3911-3918.
123. Toes, R.E.; van der Voort, E.I.; Schoenberger, S.P.; Drijfhout, J.W.; van Bloois, L.; Storm, G.; Kast, W.M.; Offringa, R.; Melief, C.J. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol., 1998, 160, 4449-4456.
124. Weijzen, S.; Meredith, S.C.; Velders, M.P.; Elmishad, A.G.; Schreiber, H.; Kast, W.M. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J. Immunol., 2001, 166, 7151-7157.
125. Koh, Y.T.; Higgins, S.A.; Weber, J.S.; Kast, W.M. Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J. Trans. Med., 2006, 4, 42.
126. Zinkernagel, R.M.; Ehl, S.; Aichele, P.; Oehen, S.; Kundig, T.; Hengartner, H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev., 1997, 156, 199-209. (Pubitemid 27197203)
127. Tagliabue, A.; Rappuoli, R. Vaccine adjuvants: the dream becomes real. Hum. Vaccin., 2008, 4, 347-349.
128. Ebensen, T.; Guzman, C.A. Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Hum. Vaccin., 2008, 4, 13-22.
129. Pedra, J.H.; Cassel, S.L.; Sutterwala, F.S. Sensing pathogens and danger signals by the inflammasome. Curr. Opin. Immunol., 2009, 21, 10-16.
130. Eisenbarth, S.C.; Colegio, O.R.; O'Connor, W.; Sutterwala, F.S.; Flavell, R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature, 2008, 453, 1122-1126.
131. Khong, H.T.; Yang, J.C.; Topalian, S.L.; Sherry, R.M.; Mavroukakis, S.A.; White, D.E.; Rosenberg, S.A. Immunization of HLAA* 0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother., 2004, 27, 472-477.
132. Phan, G.Q.; Touloukian, C.E.; Yang, J.C.; Restifo, N.P.; Sherry, R.M.; Hwu, P.; Topalian, S.L.; Schwartzentruber, D.J.; Seipp, C.A.; Freezer, L.J.; Morton, K.E.; Mavroukakis, S.A.; White, D.E.; Rosenberg, S.A. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother., 2003, 26, 349-356.
133. Hersey, P.; Menzies, S.W.; Coventry, B.; Nguyen, T.; Farrelly, M.; Collins, S.; Hirst, D.; Johnson, H. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol. Immunother., 2005, 54, 208-218. (Pubitemid 40174239)
134. Diefenbach, C.S.; Gnjatic, S.; Sabbatini, P.; Aghajanian, C.; Hensley,
135. Romero, P.; Cerottini, J.C.; Speiser, D.E. The human T cell response to melanoma antigens. Adv. Immunol., 2006, 92, 187-224.
136. Boon, T.; Coulie, P.G.; Van den Eynde, B.J.; van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol., 2006, 24, 175-208.
137. Parmiani, G.; De Filippo, A.; Novellino, L.; Castelli, C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol., 2007, 178, 1975-1979. (Pubitemid 46233392)
138. Dalgleish, A.; Pandha, H. Tumor antigens as surrogate markers and targets for therapy and vaccines. Adv. Cancer Res., 2007, 96, 175-190. (Pubitemid 44855851)
139. Pardoll, D.M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, 1999, 96, 5340-5342.
140. Lankat-Buttgereit, B.; Tampe, R. The transporter associated with antigen processing: function and implications in human diseases. Physiol. Rev., 2002, 82, 187-204. (Pubitemid 34654218)
141. Carreno, B.M.; Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol., 2002, 20, 29-53. (Pubitemid 34293419)
142. Schwartz, R.H. T cell anergy. Annu. Rev. Immunol., 2003, 21, 305-334.
143. La Motte, R.N.; Sharpe, A.H.; Bluestone, J.A.; Mokyr, M.B. Host B7-1 and B7-2 costimulatory molecules contribute to the eradica tion of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism. J. Immunol., 1999, 162, 4817-4823.
144. Greiner, J.W.; Zeytin, H.; Anver, M.R.; Schlom, J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res., 2002, 62, 6944-6951. (Pubitemid 35424085)
145. Briones, J.; Timmerman, J.M.; Panicalli, D.L.; Levy, R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J. Natl. Cancer Inst., 2003, 95, 548-555. (Pubitemid 36511626)
146. NCT00053170. Phase I/II Study of Vaccinia-CEA-TRICOM Vaccine Before Dose-Intensive Induction Chemotherapy and Fowlpox-CEA-TRICOM Vaccine After Dose-Intensive Induction Chemotherapy and Immune Depletion in Patients With Previously Untreated Metastatic Breast Cancer: http://clinicaltrials.gov/ct/ show/NCT00048893, (ongoing study).
147. NCT00088933. Phase II Randomized Pilot Study of Recombinant Vaccinia-CEA-TRICOM Vaccine Followed By Recombinant Fowlpox-CEA-TRICOM Vaccine and Sargramostim (GM-CSF) With Versus Without Docetaxel in Patients With CEA-Expressing Metastatic Lung or Colorectal Cancer: http://clinicaltrials.gov/ ct/show/NCT00088933, (ongoing study).
148. NCT00124670. Phase I Study of Vaccine Therapy Comprising Vaccinia-PSA-TRICOM Vaccine and Fowlpox-PSA-TRICOM Vaccine in Combination With Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Sargramostim (GM-CSF) in Patients With Androgen-Independent Metastatic Prostate Cancer: http://clinicaltrials.gov/ct/show/ NCT00124670, (ongoing study).
149. NCT00128622. Phase I Study Denileukin Diftitox Followed by Active Immunotherapy Comprising Autologous Dendritic Cells Infected With Recombinant Fowlpox-CEA(6D)-TRICOM Vaccine in Patients With Metastatic CEA-Expressing Malignancies: http://clinicaltrials.gov/ct/show/NCT00128622, (ongoing study).
150. NCT00217373. Phase I Study of Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine and Recombinant Fowlpox-CEA(6D)-TRICOM Vaccine in Combination With Sargramostim (GM-CSF) and Interferon alfa-2b in Patients With Locally Advanced or Metastatic Carcinoembryonic Antigen (CEA)-Expressing Carcinoma: http://clinicaltrials.gov/ ct/show/NCT00217373, (ongoing study).
151. Feder-Mengus, C.; Schultz-Thater, E.; Oertli, D.; Marti, W.R.; Heberer, M.; Spagnoli, G.C.; Zajac, P. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Hum. Gene. Ther., 2005, 16, 348-360. (Pubitemid 40471895)
152. Adamina, M.; Weber, W.P.; Rosenthal, R.; Schumacher, R.; Zajac, P.; Guller, U.; Frey, D.M.; Oertli, D.; Zuber, M.; Heberer, M.; Spagnoli, G.C. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. Contemp. Clin. Trials, 2008, 29, 165-181.
153. von Mehren, M.; Arlen, P.; Tsang, K.Y.; Rogatko, A.; Meropol, N.; Cooper, H.S.; Davey, M.; McLaughlin, S.; Schlom, J.; Weiner, L.M. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res., 2000, 6, 2219-2228.
154. Marshall, J.L.; Gulley, J.L.; Arlen, P.M.; Beetham, P.K.; Tsang, K.Y.; Slack, R.; Hodge, J.W.; Doren, S.; Grosenbach, D.W.; Hwang, J.; Fox, E.; Odogwu, L.; Park, S.; Panicali, D.; Schlom, J. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)- TRICOM, with and without granulocyte-macrophage colonystimulating factor, in patients with carcinoembryonic antigenexpressing carcinomas. J. Clin. Oncol., 2005, 23, 720-731. (Pubitemid 46224171)
155. Morse, M.A.; Clay, T.M.; Hobeika, A.C.; Osada, T.; Khan, S.; Chui, S.; Niedzwiecki, D.; Panicali, D.; Schlom, J.; Lyerly, H.K. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res., 2005, 11, 3017-3024.
156. Chen, L.; McGowan, P.; Ashe, S.; Johnston, J.; Li, Y.; Hellstrom, I.; Hellstrom, K.E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med., 1994, 179, 523-532. (Pubitemid 24979049)
157. Banchereau, J.; Palucka, A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol., 2005, 5, 296-306. (Pubitemid 40516155)
158. Trombetta, E.S.; Mellman, I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol., 2005, 23, 975-1028. (Pubitemid 40563191)
159. Watts, T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol., 2005, 23, 23-68. (Pubitemid 40563164)
160. French, R.R.; Chan, H.T.; Tutt, A.L.; Glennie, M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med., 1999, 5, 548-553.
161. Sotomayor, E.M.; Borrello, I.; Tubb, E.; Rattis, F.M.; Bien, H.; Lu, Z.; Fein, S.; Schoenberger, S.; Levitsky, H.I. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med., 1999, 5, 780-787.
162. Young, L.S.; Eliopoulos, A.G.; Gallagher, N.J.; Dawson, C.W. CD40 and epithelial cells: across the great divide. Immunol. Today, 1998, 19, 502-506.
163. Francisco, J.A.; Donaldson, K.L.; Chace, D.; Siegall, C.B.; Wahl, A.F. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Res., 2000, 60, 3225-3231.
164. van Mierlo, G.J.; den Boer, A.T.; Medema, J.P.; van der Voort, E.I.; Fransen, M.F.; Offringa, R.; Melief, C.J.; Toes, R.E. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA, 2002, 99, 5561-5566.
165. Hanks, B.A.; Jiang, J.; Singh, R.A.; Song, W.; Barry, M.; Huls, M.H.; Slawin, K.M.; Spencer, D.M. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat. Med., 2005, 11, 130-137.
166. Melero, I.; Hervas-Stubbs, S.; Glennie, M.; Pardoll, D.M.; Chen, L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer, 2007, 7, 95-106. (Pubitemid 46160986)
167. Davis, I.D.; Chen, Q.; Morris, L.; Quirk, J.; Stanley, M.; Tavarnesi, M.L.; Parente, P.; Cavicchiolo, T.; Hopkins, W.; Jackson, H.; Dimopoulos, N.; Tai, T.Y.; MacGregor, D.; Browning, J.; Svobodova, S.; Caron, D.; Maraskovsky, E.; Old, L.J.; Chen, W.; Cebon, J. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J. Immunother., 2006, 29, 499-511. (Pubitemid 44395275)
168. Biagi, E.; Rousseau, R.; Yvon, E.; Schwartz, M.; Dotti, G.; Foster, A.; Havlik-Cooper, D.; Grilley, B.; Gee, A.; Baker, K.; Carrum, G.; Rice, L.; Andreeff, M.; Popat, U.; Brenner, M. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin. Cancer Res., 2005, 11, 6916-6923. (Pubitemid 41428749)
169. NCT00101166. Phase II Study of Vaccine Therapy Comprising Autologous Tumor Cells and a Sargramostim (GM-CSF)-Producing and CD40L-Expressing Cell Line (GM.CD40L) in Patients With Stage IIIC or IV Malignant Melanoma: http://clinicaltrials.gov/ct/show/NCT00101166, (ongoing study).
170. NCT00101101. Phase II Study of Vaccine Therapy Comprising Autologous Tumor Cells and a Sargramostim (GM-CSF)-Producing and CD40L-Expressing Cell Line (GM.CD40L) Combined With Low-Dose Interleukin-2 After Conventional Chemotherapy in Patients With Relapsed or De Novo Stage II, III, or IV Mantle Cell Lymphoma: http://clinicaltrials.gov/ct/show/NCT00101101, (ongoing study).
171. NCT00309829. Phase II Study of Vaccination Comprising Autologous Dendritic Cells Transfected With Autologous Tumor mRNA and Human CD40 Ligand in Patients With Newly Diagnosed Stage IV Clear Cell Renal Cell Carcinoma: http://clinicaltrials.gov/ct/ show/NCT00309829, (ongoing study).
172. Gilliet, M.; Liu, Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med., 2002, 195, 695-704.
173. Greenwald, R.J.; Freeman, G.J.; Sharpe, A.H. The B7 family revisited. Annu. Rev. Immunol., 2005, 23, 515-548.
174. Subudhi, S.K.; Alegre, M.L.; Fu, Y.X. The balance of immune responses: costimulation verse coinhibition. J. Mol. Med., 2005, 83, 193-202.
175. Peggs, K.S.; Quezada, S.A.; Korman, A.J.; Allison, J.P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol., 2006, 18, 206-213. (Pubitemid 43327304)
176. Leach, D.R.; Krummel, M.F.; Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996, 271, 1734-1736.
177. van Elsas, A.; Sutmuller, R.P.; Hurwitz, A.A.; Ziskin, J.; Villasenor, J.; Medema, J.P.; Overwijk, W.W.; Restifo, N.P.; Melief, C.J.; Offringa, R.; Allison, J.P. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med., 2001, 194, 481-489.
178. Hurwitz, A.A.; Foster, B.A.; Kwon, E.D.; Truong, T.; Choi, E.M.; Greenberg, N.M.; Burg, M.B.; Allison, J.P. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res., 2000, 60, 2444-2448.
179. Hodi, F.S.; Mihm, M.C.; Soiffer, R.J.; Haluska, F.G.; Butler, M.; Seiden, M.V.; Davis, T.; Henry-Spires, R.; MacRae, S.; Willman, A.; Padera, R.; Jaklitsch, M.T.; Shankar, S.; Chen, T.C.; Korman, A.; Allison, J.P.; Dranoff, G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA, 2003, 100, 4712-4717. (Pubitemid 36457795)
180. Phan, G.Q.; Yang, J.C.; Sherry, R.M.; Hwu, P.; Topalian, S.L.; Schwartzentruber, D.J.; Restifo, N.P.; Haworth, L.R.; Seipp, C.A.; Freezer, L.J.; Morton, K.E.; Mavroukakis, S.A.; Duray, P.H.; Steinberg, S.M.; Allison, J.P.; Davis, T.A.; Rosenberg, S.A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 2003, 100, 8372-8377. (Pubitemid 36842552)
181. Ribas, A.; Camacho, L.H.; Lopez-Berestein, G.; Pavlov, D.; Bulanhagui, C.A.; Millham, R.; Comin-Anduix, B.; Reuben, J.M.; Seja, E.; Parker, C.A.; Sharma, A.; Glaspy, J.A.; Gomez-Navarro, J. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol., 2005, 23, 8968-8977. (Pubitemid 46217464)
182. Beck, K.E.; Blansfield, J.A.; Tran, K.Q.; Feldman, A.L.; Hughes, M.S.; Royal, R.E.; Kammula, U.S.; Topalian, S.L.; Sherry, R.M.; Kleiner, D.; Quezado, M.; Lowy, I.; Yellin, M.; Rosenberg, S.A.; Yang, J.C. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol., 2006, 24, 2283-2289.
183. Weber, J.S. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res., 2006, 16, 379-383.
184. Ribas, A. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol., 2008, 26, Abstract LBA9011.
185. NCT00636168. Efficacy study of ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanoma: http://clinicaltrials.gov/show/NCT00636168, Ongoing study.
186. Sanderson, K.; Scotland, R.; Lee, P.; Liu, D.; Groshen, S.; Snively, J.; Sian, S.; Nichol, G.; Davis, T.; Keler, T.; Yellin, M.; Weber, J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol., 2005, 23, 741-750. (Pubitemid 46224173)
187. NCT00094653. MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma: http://clinicaltrials.gov/show/NCT00094653, (ongoing study).
188. Matzinger, P. The danger model: a renewed sense of self. Science, 2002, 296, 301-305. (Pubitemid 34303674)
189. Dredge, K.; Marriott, J.B.; Todryk, S.M.; Dalgleish, A.G. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol. Immunother., 2002, 51, 521-531.
190. Touloukian, C.E.; Leitner, W.W.; Schnur, R.E.; Robbins, P.F.; Li, Y.; Southwood, S.; Sette, A.; Rosenberg, S.A.; Restifo, N.P. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J. Immunol., 2003, 170, 1579-1585.
191. Wei, Y.Q.; Huang, M.J.; Yang, L.; Zhao, X.; Tian, L.; Lu, Y.; Shu, J.M.; Lu, C.J.; Niu, T.; Kang, B.; Mao, Y.Q.; Liu, F.; Wen, Y.J.; Lei, S.; Luo, F.; Zhou, L.Q.; Peng, F.; Jiang, Y.; Liu, J.Y.; Zhou, H.; Wang, Q.R.; He, Q.M.; Xiao, F.; Lou, Y.Y.; Xie, X.J.; Li, Q.; Wu, Y.; Ding, Z.Y.; Hu, B.; Hu, M.; Zhang, W. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc. Natl. Acad. Sci. USA, 2001, 98, 11545-11550. (Pubitemid 32928765)
192. Pupa, S.M.; Iezzi, M.; Di Carlo, E.; Invernizzi, A.; Cavallo, F.; Meazza, R.; Comes, A.; Ferrini, S.; Musiani, P.; Menard, S. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res., 2005, 65, 1071-1078. (Pubitemid 40216470)
193. Deriy, L.; Ogawa, H.; Gao, G.P.; Galili, U. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene. Cancer Gene. Ther., 2005, 12, 528-539. (Pubitemid 40686593)
194. Rossi, G.R.; Mautino, M.R.; Unfer, R.C.; Seregina, T.M.; Vahanian, N.; Link, C.J. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes. Cancer Res., 2005, 65, 10555-10561.
195. Fong, L.; Brockstedt, D.; Benike, C.; Breen, J.K.; Strang, G.; Ruegg, C.L.; Engleman, E.G. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol., 2001, 167, 7150-7156. (Pubitemid 33144213)
196. Hemstreet, G.P.; Vahanian, N.; Tennant, L.; Rossi, G.; Ramsey, J.; Seregina, T.; Hauke, R.; Enke, C.; Linke, C. Phase I study of an antitumor vaccination (hyperacute vaccine) using alpha (1,3) galactosyltransferase expressing allogeneic tumor cells in patients with metastatic and hormone refractory prostate cancer. Prostate Cancer Symposium 2006 2006.
197. NCT00393783. Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity: http://clinicaltrials. gov/show/NCT00393783, (ongoing study).
198. NCT00075790. Phase I/II Study of Vaccination Comprising a-1,3-Galactosyltransferase-Expressing Allogeneic Tumor Cells (HyperAcute™ Lung Cancer Vaccine) in Patients With Advanced Refractory or Recurrent Non-Small Cell Lung Cancer: http://clinicaltrials.gov/ct/show/NCT00073398, (ongoing study).
199. NCT00255827. Vaccine Treatment for Surgically Resected Pancreatic Cancer: http://clinicaltrials.gov/show/NCT00255827, (ongoing study).
200. Borrello, I.; Pardoll, D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev., 2002, 13, 185-193. (Pubitemid 34229392)
201. Colombo, M.P.; Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev., 2002, 13, 155-168.
202. Ribas, A.; Amarnani, S.N.; Buga, G.M.; Butterfield, L.H.; Dissette, V.B.; McBride, W.H.; Glaspy, J.A.; Ignarro, L.J.; Economou, J.S. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene. Ther., 2002, 9, 875-883.
203. Serafini, P.; Carbley, R.; Noonan, K.A.; Tan, G.; Bronte, V.; Borrello, I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res., 2004, 64, 6337-6343. (Pubitemid 39129439)
204. Parmiani, G.; Castelli, C.; Pilla, L.; Santinami, M.; Colombo, M.; Rivoltini, L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol., 2007, 18, 226-232. (Pubitemid 46323086)
205. Moschos, S.; Kirkwood, J.M. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev., 2007, 18, 451-458.
206. Na, I.K.; Keilholz, U.; Letsch, A.; Bauer, S.; Asemissen, A.M.; Nagorsen, D.; Thiel, E.; Scheibenbogen, C. Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells. Cancer Immunol. Immunother., 2007, 56, 391-396. (Pubitemid 46035907)
207. Kirkwood, J.M.; Lee, S.; Moschos, S.J.; Albertini, M.R.; Michalak, J.C.; Sander, C.; Whiteside, T.; Butterfield, L.H.; Weiner, L. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res., 2009, 15, 1443-1451.
208. Aebersold, R.; Auffray, C.; Baney, E.; Barillot, E.; Brazma, A.; Brett, C.; Brunak, S.; Butte, A.; Califano, A.; Celis, J.; Cufer, T.; Ferrell, J.; Galas, D.; Gallahan, D.; Gatenby, R.; Goldbeter, A.; Hace, N.; Henney, A.; Hood, L.; Iyengar, R.; Jackson, V.; Kallioniemi, O.; Klingmuller, U.; Kolar, P.; Kolch, W.; Kyriakopoulou, C.; Laplace, F.; Lehrach, H.; Marcus, F.; Matrisian, L.; Nolan, G.; Pelkmans, L.; Potti, A.; Sander, C.; Seljak, M.; Singer, D.; Sorger, P.; Stunnenberg, H.; Superti-Furga, G.; Uhlen, M.; Vidal, M.; Weinstein, J.; Wigle, D.; Williams, M.; Wolkenhauer, O.; Zhivotovsky, B.; Zinovyev, A.; Zupan, B. Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol. Oncol., 2009, 3, 9-17.
209. Binder, R.J.; Han, D.K.; Srivastava, P.K. CD91: a receptor for heat shock protein gp96. Nat. Immunol., 2000, 1, 151-155.
210. Srivastava, P.K. Immunotherapy of human cancer: lessons from mice. Nat. Immunol., 2000, 1, 363-366.
211. Parmiani, G.; Testori, A.; Maio, M.; Castelli, C.; Rivoltini, L.; Pilla, L.; Belli, F.; Mazzaferro, V.; Coppa, J.; Patuzzo, R.; Sertoli, M.R.; Hoos, A.; Srivastava, P.K.; Santinami, M. Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res., 2004, 10, 8142-8146. (Pubitemid 40053371)
212. Daniels, G.A.; Sanchez-Perez, L.; Diaz, R.M.; Kottke, T.; Thompson, J.; Lai, M.; Gough, M.; Karim, M.; Bushell, A.; Chong, H.; Melcher, A.; Harrington, K.; Vile, R.G. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol., 2004, 22, 1125-1132.
213. Mazzaferro, V.; Coppa, J.; Carrabba, M.G.; Rivoltini, L.; Schiavo, M.; Regalia, E.; Mariani, L.; Camerini, T.; Marchiano, A.; Andreola, S.; Camerini, R.; Corsi, M.; Lewis, J.J.; Srivastava, P.K.; Parmiani, G. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res., 2003, 9, 3235-3245. (Pubitemid 37082717)
214. Belli, F.; Testori, A.; Rivoltini, L.; Maio, M.; Andreola, G.; Sertoli, M.R.; Gallino, G.; Piris, A.; Cattelan, A.; Lazzari, I.; Carrabba, M.; Scita, G.; Santantonio, C.; Pilla, L.; Tragni, G.; Lombardo, C.; Arienti, F.; Marchiano, A.; Queirolo, P.; Bertolini, F.; Cova, A.; Lamaj, E.; Ascani, L.; Camerini, R.; Corsi, M.; Cascinelli, N.; Lewis, J.J.; Srivastava, P.; Parmiani, G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol., 2002, 20, 4169-4180. (Pubitemid 35191019)
215. Testori, A.; Richards, J.; Whitman, E.; Mann, G.B.; Lutzky, J.; Camacho, L.; Parmiani, G.; Tosti, G.; Kirkwood, J.M.; Hoos, A.; Yuh, L.; Gupta, R.; Srivastava, P.K. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol., 2008, 26, 955-962.
216. Wood, C.; Srivastava, P.; Bukowski, R.; Lacombe, L.; Gorelov, A.I.; Gorelov, S.; Mulders, P.; Zielinski, H.; Hoos, A.; Teofilovici, F.; Isakov, L.; Flanigan, R.; Figlin, R.; Gupta, R.; Escudier, B. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet, 2008, 372, 145-154.
217. Uematsu, S.; Akira, S. Toll-like receptors and innate immunity. J. Mol. Med., 2006, 84, 712-725.
218. Tormo, D.; Ferrer, A.; Bosch, P.; Gaffal, E.; Basner-Tschakarjan, E.; Wenzel, J.; Tuting, T. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res., 2006, 66, 5427-5435. (Pubitemid 43844970)
219. Krieg, A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov., 2006, 5, 471-484. (Pubitemid 44136959)
220. Vicari, A.P.; Chiodoni, C.; Vaure, C.; Ait-Yahia, S.; Dercamp, C.; Matsos, F.; Reynard, O.; Taverne, C.; Merle, P.; Colombo, M.P.; O'Garra, A.; Trinchieri, G.; Caux, C. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med., 2002, 196, 541-549. (Pubitemid 34940992)
221. NCT00145145. Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma: http://clinicaltrials. gov/ct/show/NCT00145145, (ongoing study).
222. NCT00112229. Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients: http://clinicaltrials.gov/show/NCT00112229, (ongoing study).
223. Wittig, B.; Marten, A.; Dorbic, T.; Weineck, S.; Min, H.; Niemitz, S.; Trojaneck, B.; Flieger, D.; Kruopis, S.; Albers, A.; Loffel, J.; Neubauer, A.; Albers, P.; Muller, S.; Sauerbruch, T.; Bieber, T.; Huhn, D.; Schmidt-Wolf, I.G. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum. Gene. Ther., 2001, 12, 267-278. (Pubitemid 32163898)
224. Speiser, D.E.; Lienard, D.; Rufer, N.; Rubio-Godoy, V.; Rimoldi, D.; Lejeune, F.; Krieg, A.M.; Cerottini, J.C.; Romero, P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest., 2005, 115, 739-746.
225. Fourcade, J.; Kudela, P.; Andrade Filho, P.A.; Janjic, B.; Land, S.R.; Sander, C.; Krieg, A.; Donnenberg, A.; Shen, H.; Kirkwood, J.M.; Zarour, H.M. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J. Immunother., 2008, 31, 781-791.
226. McInturff, J.E.; Modlin, R.L.; Kim, J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J. Invest. Dermatol., 2005, 125, 1-8. (Pubitemid 40981417)
227. Agrawal, S.; Kandimalla, E.R. Role of Toll-like receptors in antisense and siRNA [corrected]. Nat. Biotechnol., 2004, 22, 1533-1537. (Pubitemid 40039455)
228. Applequist, S.E.; Rollman, E.; Wareing, M.D.; Liden, M.; Rozell, B.; Hinkula, J.; Ljunggren, H.G. Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J. Immunol., 2005, 175, 3882-3891.
229. Craft, N.; Bruhn, K.W.; Nguyen, B.D.; Prins, R.; Lin, J.W.; Liau, L.M.; Miller, J.F. The TLR7 agonist imiquimod enhances the antimelanoma effects of a recombinant Listeria monocytogenes vaccine. J. Immunol., 2005, 175, 1983-1990.
230. Prins, R.M.; Craft, N.; Bruhn, K.W.; Khan-Farooqi, H.; Koya, R.C.; Stripecke, R.; Miller, J.F.; Liau, L.M. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol., 2006, 176, 157-164.
231. Woodmansee, C.; Pillow, J.; Skinner, R.B., Jr. The role of topical immune response modifiers in skin cancer. Drugs, 2006, 66, 1657-1664.
232. Feyerabend, S.; Stevanovic, S.; Gouttefangeas, C.; Wernet, D.; Hennenlotter, J.; Bedke, J.; Dietz, K.; Pascolo, S.; Kuczyk, M.; Rammensee, H.G.; Stenzl, A. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate, 2009, 69, 917-927
233. Shackleton, M.; Davis, I.D.; Hopkins, W.; Jackson, H.; Dimopoulos, N.; Tai, T.; Chen, Q.; Parente, P.; Jefford, M.; Masterman, K.A.; Caron, D.; Chen, W.; Maraskovsky, E.; Cebon, J. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun., 2004, 4, 9. (Pubitemid 39363886)
234. NCT00304057. Phase II Randomized Study of Adjuvant gp100 Peptide Immunization With or Without Montanide ISA 51 and/or Imiquimod in Patients With Resected High-Risk Melanoma: http://clinicaltrials.gov/ct/show/NCT00304057, (ongoing study).
235. Yang, Y.; Huang, C.T.; Huang, X.; Pardoll, D.M. Persistent Toll-like receptor signals are required for reversal of regulatory T cellmediated CD8 tolerance. Nat. Immunol., 2004, 5, 508-515.
236. Peng, G.; Guo, Z.; Kiniwa, Y.; Voo, K.S.; Peng, W.; Fu, T.; Wang, D.Y.; Li, Y.; Wang, H.Y.; Wang, R.F. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science, 2005, 309, 1380-1384.
237. Killeen, S.D.; Wang, J.H.; Andrews, E.J.; Redmond, H.P. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br. J. Cancer, 2006, 95, 247-252.
238. Tsan, M.F. Toll-like receptors, inflammation and cancer. Semin. Cancer Biol., 2006, 16, 32-37.
239. Huang, B.; Zhao, J.; Li, H.; He, K.L.; Chen, Y.; Chen, S.H.; Mayer, L.; Unkeless, J.C.; Xiong, H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res., 2005, 65, 5009-5014. (Pubitemid 40827306)
240. Slingluff, C.L., Jr.; Petroni, G.R.; Chianese-Bullock, K.A.; Smolkin, M.E.; Hibbitts, S.; Murphy, C.; Johansen, N.; Grosh, W.W.; Yamshchikov, G.V.; Neese, P.Y.; Patterson, J.W.; Fink, R.; Rehm, P.K. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res., 2007, 13, 6386-6395.
241. Markovic, S.N.; Suman, V.J.; Ingle, J.N.; Kaur, J.S.; Pitot, H.C.; Loprinzi, C.L.; Rao, R.D.; Creagan, E.T.; Pittelkow, M.R.; Allred, J.B.; Nevala, W.K.; Celis, E. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am. J. Clin. Oncol., 2006, 29, 352-360. (Pubitemid 44197539)
242. Chatterjee, M.; Draghici, S.; Tainsky, M.A. Immunotheranostics: breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays. Curr. Opin. Drug Discov. Dev., 2006, 9, 380-385.
243. Mocellin, S.; Wang, E.; Panelli, M.; Pilati, P.; Marincola, F.M. DNA array-based gene profiling in tumor immunology. Clin. Cancer Res., 2004, 10, 4597-4606. (Pubitemid 38955508)
244. Gunawardana, C.G.; Diamandis, E.P. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett., 2007, 249, 110-119.
245. Gillis, J.S. Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy. J. Trans. Med., 2006, 4, 27.
246. Murata, S.; Ladle, B.H.; Kim, P.S.; Lutz, E.R.; Wolpoe, M.E.; Ivie, S.E.; Smith, H.M.; Armstrong, T.D.; Emens, L.A.; Jaffee, E.M.; Reilly, R.T. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J. Immunol., 2006, 176, 974-983.
247. Quezada, S.A.; Peggs, K.S.; Curran, M.A.; Allison, J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest., 2006, 116, 1935-1945.
248. Nava-Parada, P.; Forni, G.; Knutson, K.L.; Pease, L.R.; Celis, E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res., 2007, 67, 1326-1334. (Pubitemid 46270793)
249. Pedersen, A.E.; Buus, S.; Claesson, M.H. Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett., 2006, 235, 229-238.
250. Davila, E.; Kennedy, R.; Celis, E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res., 2003, 63, 3281-3288.
251. Pilla, L.; Patuzzo, R.; Rivoltini, L.; Maio, M.; Pennacchioli, E.; Lamaj, E.; Maurichi, A.; Massarut, S.; Marchiano, A.; Santantonio, C.; Tosi, D.; Arienti, F.; Cova, A.; Sovena, G.; Piris, A.; Nonaka, D.; Bersani, I.; Di Florio, A.; Luigi, M.; Srivastava, P.K.; Hoos, A.; Santinami, M.; Parmiani, G. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol. Immunother., 2006, 55, 958-968. (Pubitemid 43673585)
252. Dessureault, S.; Noyes, D.; Lee, D.; Dunn, M.; Janssen, W.; Cantor, A.; Sotomayor, E.; Messina, J.; Antonia, S.J. A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing By-stander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease. Ann. Surg. Oncol., 2007, 14, 869-884.
253. Kocak, E.; Lute, K.; Chang, X.; May, K.F., Jr.; Exten, K.R.; Zhang, H.; Abdessalam, S.F.; Lehman, A.M.; Jarjoura, D.; Zheng, P.; Liu, Y. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res., 2006, 66, 7276-7284. (Pubitemid 44197709)
254. Igney, F.H.; Krammer, P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol., 2002, 71, 907-920.
255. Schimmer, A.D.; Thomas, M.P.; Hurren, R.; Gronda, M.; Pellecchia, M.; Pond, G.R.; Konopleva, M.; Gurfinkel, D.; Mawji, I.A.; Brown, E.; Reed, J.C. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res., 2006, 66, 2367-2375.
256. Ravi, R.; Fuchs, E.J.; Jain, A.; Pham, V.; Yoshimura, K.; Prouser, T.; Jalla, S.; Zhou, X.; Garrett-Mayer, E.; Kaufmann, S.H.; Schulick, R.D.; Pardoll, D.M.; Bedi, A. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res., 2006, 66, 1730-1739. (Pubitemid 43259958)
257. Lickliter, J.D.; Cox, J.; McCarron, J.; Martinez, N.R.; Schmidt, C.W.; Lin, H.; Nieda, M.; Nicol, A.J. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction. Br. J. Cancer, 2007, 96, 600-608.
258. Kang, T.H.; Lee, J.H.; Song, C.K.; Han, H.D.; Shin, B.C.; Pai, S.I.; Hung, C.F.; Trimble, C.; Lim, J.S.; Kim, T.W.; Wu, T.C. Epigallocatechin-3- gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res., 2007, 67, 802-811. (Pubitemid 46192221)